Isolation and in Vitro Characterization of Specific Bacteriophages against Methicillin-Resistant Staphylococcus aureus

Document Type : Original Research

Authors
M. R. Esmaeilzadeh 1
S. Sabzi 2
A. Hajihossein Tabrizi 3
1 Department of Pathobiology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
2 Department of Molecular Biology, Pasteur Institute, Tehran, Iran
3 Department of Biology, School of Basic Sciences, Islamic Azad University, Qods city Branch, Tehran, Iran
10.52547/iem.8.2.121
Abstract
Backgrounds: Bacteriophage therapy could be an alternative strategy for the treatment of antibiotic-resistant bacteria. This study aimed to evaluate the antibacterial activities of isolated bacteriophages against methicillin-resistant Staphylococcus aureus (MRSA) isolates.

Materials & Methods: A total of 16 clinical isolates of MRSA were collected from medical diagnostic laboratories in Tehran, Iran. A specific bacteriophage was isolated from hospital sewage using double-layer agar. Phage morphology was evaluated by transmission electron microscopy (TEM). Different bacteria were selected to determine the bacteriophage host range using spot test. Phage susceptibility to temperature and pH was evaluated by double-layer agar method. In vitro assay was carried out on human epithelial type 2 (HEp-2) cells to investigate the effect of bacteriophage on the adhesion of MRSA to human epithelial cells.

Findings: TEM suggested the Myoviridae family for the isolated phage. The effective titer of bacteriophages was 1.8×107 PFU/mL. The isolated bacteriophage was stable at 4 ˚C and pH=8. The isolated bacteriophage was specific for all clinical isolates of MRSA and had no lytic activity against other pathogenic bacteria. In evaluating the binding and invasion of MRSA to the HEp-2 cell line, as expected, the lytic activity of specific bacteriophages was observed following inoculation.

Conclusion: The specificity and lytic activity of this phage on MRSA and MRSA-infected HEp-2 cell line emphasized that the isolated bacteriophage may serve as an effective prophylactic and alternative therapeutic agent in hospital settings.

Keywords

Subjects

[1] Davies J, Davies D. Origins and evolution of antibiotic resistance. MMBR 2010; 74(3): 417–433
[2] David MZ, Daum RS. Community-associated methicillin-resistant Staphylococcus aureus: epidemiology and clinical consequences of an emerging epidemic. Clin Microbiol Rev 2010; 23: 616-687.
[3] Askari E, Soleymani F, Arianpoor A, Tabatabai SM, Amini A, NaderiNasab M. Epidemiology of mecA-methicillin resistant Staphylococcus aureus (MRSA) in Iran: a systematic review and meta-analysis. Iran J Basic Med Sci 2012; 15(5): 1010- 1019.
[4] Li B, Webster TJ. Bacteria antibiotic resistance: New challenges and opportunities for implant‐associated orthopedic infections. J Orthop Res 2018; 36: 22-32.
[5] Moghadam, M.T., et al., Bacteriophages, a new therapeutic solution for inhibiting multidrug-resistant bacteria causing wound infection: lesson from animal models and clinical trials. Drug Design, Development and Therapy, 2020. 14: p. 1867.
[6] Summers WC. Félix d’Hérelle and the origins of molecular biology. Yale University Press, New Haven and Londo, 1999.
[7] Ho K. Bacteriophage therapy for bacterial infections: rekindling a memory from the pre-antibiotics era. Perspect Biol Med 2001;44:1-16.
[8] Merril CR, Biswas B, Carlton R, Jensen NC, Creed GJ, Zullo S, et al. Long-circulating bacteriophage as antibacterial agents. Proc Natl Acad Sci 1996;93:3188-92.
[9] Drulis-Kawa Z, Majkowska-Skrobek G, Maciejewska B, Delattre A-S, Lavigne R. Learning from bacteriophages-advantages and limitations of phage and phage-encoded protein applications. Curr Protein Pept Sci 2012;13:699-722.
[10] Divya Ganeshan S, Hosseinidoust Z. Phage therapy with a focus on the human microbiota. J Antibiot 2019;8:131.
[11] Lin DM, Koskella B, Lin HC. Phage therapy: An alternative to antibiotics in the age of multi-drug resistance. World J Gastrointest Pharmacol Ther 2017; 8(3): 162 -173.
[12] Weber-Dąbrowska B, Mulczyk M, Górski A. Bacteriophage therapy of bacterial infections: an update of our institute’s experience. Arch Immunol Ther Exp 2000; 48(6): 547-551.
[13] Romero-Calle D, Guimarães Benevides R, Góes-Neto A, Billington C. Bacteriophages as alternatives to antibiotics in clinical care. J Antibiot 2019;8:138.
[14] Wong CL, Sieo CC, Tan WS, Abdullah N, Hair-Bejo M, Abu J, et al. Evaluation of a lytic bacteriophage, Φ st1, for biocontrol of Salmonella enterica serovar Typhimurium in chickens. Int J Food Microbiol 2014;172:92-101.
[15] Wagenaar JA, Van Bergen MA, Mueller MA, Wassenaar TM, Carlton RM. Phage therapy reduces Campylobacter jejuni colonization in broilers. Vet Microbiol 2005;109:275-83.
[16] Tahmasbi, F., et al., Biofilm formation and molecular characterization of methicillin-resistant Staphylococcus aureus strains isolated from the patients, personnel, air and environment of ICUs. Gene Reports, 2020. 20: p. 100736.
[17] Wang Z, Zheng P, Ji W, Fu Q, Wang H, Yan Y, et al. SLPW: A virulent bacteriophage targeting methicillin-resistant Staphylococcus aureus in vitro and in vivo. Front Microbiol 2016;7:934.
[18] Nobrega FL, Costa AR, Kluskens LD, Azeredo J. Revisiting phage therapy: new applications for old resources. Trends Microbiol 2015;23:185-91.
[19] Shende R, Hirpurkar S, Sannat C, Rawat N, Pandey V. Isolation and characterization of bacteriophages with lytic activity against common bacterial pathogens. Vet World 2017;10:973.
[20] Smith HW, Huggins MB, Shaw KM. The control of experimental Escherichia coli diarrhoea in calves by means of bacteriophages. J Gen Microbiol 1987;133:1111-26.
[21] Deghorain M, Van Melderen L. The Staphylococci phages family: an overview. Viruses 2012; 4(12): 3316-3335.
[22] Melo LDR, Brandão A, Akturk E, Santos SB, Azeredo J. Characterization of a New Staphylococcus aureus Kayvirus Harboring a Lysin Active against Biofilms. Viruses 2018; 10(4):182-198.
[23] Kraushaar, B., Thanh, M.D., Hammerl, J.A. et al. Isolation and characterization of phages with lytic activity against methicillin-resistant Staphylococcus aureus strains belonging to clonal complex 398. Arch Virol 2013; 158, 2341–2350.
[24] Nasser A, Azizian R, Tabasi M, Khezerloo JK, Heravi FS, Kalani MT, et al. Specification of Bacteriophage Isolated Against Clinical Methicillin-Resistant Staphylococcus Aureus. Osong Public Health Res Perspect 2019; 10(1): 20-24.
[25] Ptashne M. Lambda's switch: lessons from a module swap. Curr Biol 2006;16: 459-462.
[26] Łubowska N, Grygorcewicz B, Kosznik-Kwaśnicka K, Zauszkiewicz-Pawlak A, Węgrzyn A, et al. Characterization of the Three New Kayviruses and Their Lytic Activity Against Multidrug-Resistant Staphylococcus aureus. Microorganisms 2019; 7(10): 471-488.
[27] Paolozzi L, Ghelardini P. The bacteriophage Mu. In: Calendar R, Abedon ST (eds) The bacteriophages. Oxford University Press, Oxford, 2006.
[28] Jończyk E, Kłak M, Międzybrodzki R, Górski A. The influence of external factors on bacteriophages-review. Folia Microbiol 2011; 56(3): 191-200.
Nasu-Nishimura Y, Taniuchi Y, Nishimura T, Sakudo A, Nakajima K, Ano Y, et al. Cellular prion protein prevents brain damage after encephalomyocarditis virus infection in mice. Archives of virology 2008;153:1007-12.
[29] Chandni P, Amrita S, Archana PV, Pradeesh B, Bipin N, Ajith M, et al. Characterization of the bacteriophages binding to human matrix molecules, Int J Biol Macromol 2017; 110: 0141-130.
Infection Epidemiology and Microbiology
Volume 8, Issue 2
June 2022
Pages 121-128